SCHEMBL4671265

SCHEMBL4671265

O=C(C=C(O)c1nc[nH]n1)c1cc(CCc2ccccc2)c(Cc2ccncc2)o1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.35
NR3C2 P08235 2/20 0.34
LTA4H P09960 1/20 0.34
CYP19A1 P11511 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
GPR52 Q9Y2T5 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PIM1 P11309 1/20 0.32
PIM2 Q9P1W9 1/20 0.32
RAB9A P51151 1/20 0.32
KDM4E B2RXH2 1/20 0.31
HIF1A Q16665 2/20 0.31
MAPK3 P27361 1/20 0.31
MAPK1 P28482 1/20 0.31
PLA2G7 Q13093 1/20 0.31
CDC7 O00311 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678767 0.93 CYP19A1 (0.36) ABCB1NR3C2LTA4HCYP19A1CYP11B1
SCHEMBL4671846 0.90 LMNA (0.35) NR3C2RAB9AKDM4EMAPK1
SCHEMBL4672722 0.84 NR3C2 (0.36) ABCB1NR3C2LTA4HCYP19A1CYP11B1
SCHEMBL4675251 0.84 ABCB1 (0.35) ABCB1LTA4HCYP19A1CYP11B1CYP11B2
SCHEMBL4674148 0.84 ABCB1 (0.35) ABCB1NR3C2LTA4HCYP19A1CYP11B1
SCHEMBL4675299 0.83 PIM1 (0.33) PIM1PIM2KDM4EMAPK1
SCHEMBL4674887 0.83 ALDH1A1 (0.33) SMN1; SMN2PIM1PIM2KDM4E
SCHEMBL4673166 0.83 PIM1 (0.31) CYP19A1CYP11B1CYP11B2PIM1PIM2
SCHEMBL4671337 0.83 LMNA (0.36) NR3C2RAB9AKDM4EMAPK1
SCHEMBL4674759 0.82 NR3C2 (0.36) ABCB1NR3C2LTA4HCYP19A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ABCB1 114/4885NR3C2 221/4885LTA4H 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.